Ionis Pharmaceuticals (NASDAQ:IONS) subsidiary Akcea Therapeutics (Pending:AKCA) launches its initial public offering of 9.62M shares of common stock at $12 - 14. Underwriters over-allotment is an additional 1.443M shares.
The late-stage biopharmaceutical firm develops antisense drugs to treat patients with serious cardiometabolic diseases caused by lipid disorders. Its most advanced candidate is Phase 3-stage volanesorsen for the treatment of familial chylomicronemia syndrome and familial partial lipodystrophy, both rare inherited lipid disorders characterized by extremely elevated triglycerides.
2016 Financials (NYSE:M): Operating Expenses: 83.5 (+36.0%); Net Loss: (83.2) (-35.5%).
Subscribe for full text news in your inbox